Key result
Renal-artery stenting fails to improve quality of life over medical therapy in atherosclerotic stenosis.
Why the study?
Does renal-artery stenting improve quality of life compared to medical therapy in patients with atherosclerotic renal-artery stenosis?
RCT (n=906)
Open-label
randomized
Yes
Does renal-artery stenting improve quality of life compared to medical therapy in patients with atherosclerotic renal-artery stenosis?
Answers are grounded in this paper and cite their sources.
Renal-artery stenting does not provide quality of life benefits over medical therapy in patients with atherosclerotic renal-artery stenosis.
BACKGROUND: Renal-artery stenosis can be associated with difficult to control hypertension, although renal-artery stenting has not been shown to improve clinical outcomes. Alternative antihypertensive medications could potentially result in quality of life benefits with renal-artery stenting. METHODS AND RESULTS: We performed a pre-specified quality of life sub-study of the CORAL trial-multicenter, randomized, open-label trial of renal-artery stenting vs. medical therapy in patients with atherosclerotic renal-artery stenosis. Longitudinal growth curve models were used to compare the Physical Symptoms Distress Index (PSDI), SF-36, and EQ-5D scores over time between treatment groups. We also sought to validate the approach of assessing quality of life in hypertension studies. Among 906 patients (mean age 69.2 ± 9.1 years, 49.7% men), symptom frequency and distress due to side effects from antihypertensive medications changed minimally over time, with no significant differences between treatment groups. There were also no clinically significant differences between treatment groups for the SF-36 and its subscales or the EQ-5D. In internal validation of the quality of life measures, the PSDI correlated well with number/type of antihypertensive medications, and generic health status measures correlated with late clinical events. CONCLUSIONS: In a large, multicenter, randomized clinical trial, we found no significant benefit of routine renal-artery stenting over medical management for the treatment of atherosclerotic renal-artery stenosis in terms of disease-specific or generic quality of life measures. As these quality of life measures are important to patients and are associated with medication compliance, future studies of antihypertensive treatments should consider including these quality of life measures as secondary outcomes. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00081731.
No takes yet. Share an insight, caveat, or question.
Arnold et al. (2024) conducted an RCT in Atherosclerotic renal-artery stenosis (n=906). Renal-artery stenting vs. Medical therapy was evaluated on Physical Symptoms Distress Index (PSDI), SF-36, and EQ-5D scores over time. Among 906 patients with atherosclerotic renal-artery stenosis, routine renal-artery stenting provided no significant benefit over medical management for quality of life measures.
Synapse has enriched 10 related papers. Consider them for comparative context: